Nasal Protollin in Early Symptomatic Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

September 22, 2022

Study Completion Date

February 21, 2023

Conditions
Alzheimer Disease (AD)
Interventions
DRUG

Protollin

For the 0.1, 0.5, and 1.0 mg dose groups, Protollin (450 μL per vial) in an aqueous buffer will be administered in two, 0.1 μL sprays, one per nostril. For the 1.5 mg dose group, Protollin (450 muL per vial) in an aqueous buffer will be administered in three, 0.1 μL sprays, two in one nostril and one in the other nostril.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

I-Mab Biopharma US Limited

INDUSTRY

lead

Brigham and Women's Hospital

OTHER